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Background: Evidence from the literature suggests diminished acetylsalicylic acid (ASA) treatment efficacy in type 2
diabetes (DM2). High on-aspirin platelet reactivity (HAPR) in DM2 has been linked to poor glycemic and lipid control.
However, there are no consistent data on the association between HAPR and insulin resistance or adipose tissue
metabolic activity. The aim of this study was to assess the relationship between laboratory response to ASA and
metabolic control, insulin resistance and adipokines in DM2.
Methods: A total of 186 DM2 patients treated with oral antidiabetic drugs and receiving 75 mg ASA daily were included
in the analysis. Response to ASA was assessed by measuring serum thromboxane B2 (TXB2) concentration and expressed
as quartiles of TXB2 level. The achievement of treatment targets in terms of glycemic and lipid control, insulin resistance
parameters (including Homeostatic Model Assessment-Insulin Resistance, HOMA-IR, index), and serum concentrations of
high-molecular weight (HMW) adiponectin, leptin and resistin, were evaluated in all patients. Univariate and multivariate
logistic regression analyses were performed to determine the predictive factors of serum TXB2 concentration above the
upper quartile and above the median.
Results: Significant trends in age, body mass index (BMI), HOMA-IR, HMW adiponectin concentration, C-reactive protein
concentration and the frequency of achieving target triglyceride levels were observed across increasing quartiles of TXB2.
In a multivariate analysis, only younger age and higher BMI were independent predictors of TXB2 concentration above
the upper quartile, while younger age and lower HMW adiponectin concentration were predictors of TXB2 concentration
above the median.
Conclusions: These results suggest that in DM2, the most important predictor of HAPR is younger age. Younger DM2
patients may therefore require total daily ASA doses higher than 75 mg, preferably as a twice-daily regimen, to achieve
full therapeutic effect. Higher BMI and lower HMW adiponectin concentration were also associated with less potent ASA
effect. This is the first study to demonstrate an association of lower adiponectin concentration with higher serum TXB2
level in patients treated with ASA.
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Treatment with acetylsalicylic acid (ASA) has proven ef-
fective in the reduction of cardiovascular morbidity and
mortality. Type 2 diabetic (DM2) patients are known to
be at a very high cardiovascular risk, therefore it could
be anticipated that they should potentially benefit the
most from ASA treatment [1]. However, results of the
Antithrombotic Trialists' Collaboration's meta-analysis
of 195 clinical trials with over 135,000 patients, includ-
ing almost 5000 diabetic patients, suggest that ASA
therapy in diabetic patients may be less effective in car-
diovascular prevention than in normoglycemic individ-
uals [2]. Concomitant DM2 also increases the risk of
high on-aspirin platelet reactivity (HAPR), defined as in-
adequate inhibition of platelet function, assessed in vitro
with laboratory tests [3-9]. According to the position
paper of the Working Group on Antiplatelet Drugs
Resistance, endorsed by the Working Group on
Thrombosis of the European Society of Cardiology, labora-
tory response to ASA treatment should be assessed with
aspirin-specific tests evaluating the degree of cyclooxygen-
ase 1 (COX-1) inhibition, either directly, by measuring
serum concentration of thromboxane B2 (TXB2) - a stable
metabolite of thromboxane A2 (COX-1 product) or indir-
ectly, by assessing platelet aggregation induced by arachi-
donic acid (COX-1 substrate) [10].
Patients with DM2 exhibit abnormalities of both platelet
and plasma hemostasis, and differ from other patients in
terms of thrombus structure and kinetics [11]. The patho-
mechanism of HAPR in patients with DM2 is complex
and, so far, not entirely understood [12,13]. It is hypothe-
sized that under hyperglycemic conditions nonenzymatic
glycation of COX-1 may competitively inhibit its acetylation
by ASA [14]. In addition, nonenzymatic glycation of platelet
membrane proteins may result in reduced membrane fluid-
ity, increasing the propensity of platelets to activate [15].
Other possible mechanisms leading to enhanced platelet
reactivity under hyperglycemia include osmotic effect of
glucose, increased activation of protein kinase C and de-
creased activation of nitric oxide (NO) - cyclic guanosine
monophosphate (cGMP) - cGMP-dependent protein kinase
pathway [15-17]. These assumptions are supported by clin-
ical studies demonstrating relationship between HAPR and
inadequate glycemic control, as well as in vitro studies
showing enhanced platelet activation, assessed using flow
cytometry, with increasing glucose concentrations despite
incubation with ASA [6,7,18-23]. Alongside with poor gly-
cemic control, HAPR in DM2 patients has been linked to
high triglyceride, total cholesterol and low-density lipo-
protein (LDL) concentrations, as well as low high-
density lipoprotein (HDL) concentration [18,20,24].
Hyperglycemia and hyperlipidemia induce oxidative
stress, which, in turn, leads to fatty acids peroxidation
and, consequently, formation of products that maychange physicochemical properties of platelet plasma
membrane or - as described for isoprostanoids - act as
ligands for platelet membrane receptors, triggering
platelet activation and aggregation via alternative path-
ways [25]. Furthermore, oxidative stress may also aug-
ment platelet reactivity indirectly, as it results in
endothelial dysfunction, diminished endothelial synthe-
sis of NO and prostacyclin, and attenuation of biological
effects of NO [15].
Much as the relationship of HAPR with glycemic and
lipid control of DM2 has been well documented, only
few small studies regarding the association of platelet re-
activity with insulin resistance and adipokine concentra-
tions have been conducted so far [5,26-28]. Among 60
healthy women, a lower insulin sensitivity index was pre-
dictive of higher urine 11-dehydro-TXB2 concentration
and improvement in insulin sensitivity resulted in de-
creasing urinary 11-dehydro-TXB2 excretion [26]. In a
group of 55 patients with DM2, higher Homeostatic
Model Assessment-Insulin Resistance (HOMA-IR) index
was an independent predictor of poor responsiveness to
ASA assessed using urine 11-dehydro-TXB2 concentra-
tion measurement [27]. Increased rates of HAPR
observed in obese patients also imply its potential asso-
ciation with insulin resistance [6,21,26]. On the other
hand, similar prevalence of poor responsiveness to ASA
in patients with type 1 and type 2 diabetes seems to
contradict such relationship [29]. Moreover, a negative
correlation of serum TXB2 concentration with body
mass index (BMI) and leptin concentration (which was
shown to positively correlate with HOMA-IR) reported
by Graziani et al. also question the previously suggested
pathogenetic role of insulin resistance in the develop-
ment of HAPR [28]. Thus, consistent data on the associ-
ation of HAPR with insulin resistance and adipose tissue
metabolic activity are lacking.
In our previous work, we have evaluated the relation-
ship between HAPR assessed with various laboratory
methods and genetic factors, clinical variables and rou-
tine laboratory parameters in DM2 [30,31]. The aim of
this study was to assess the relationship between labora-
tory response to ASA therapy and insulin resistance, adi-
pose tissue metabolic activity and the achievement of
metabolic control in DM2 patients.
Methods
Patient population and study design
The study subjects were recruited from a group of pa-
tients participating in a prospective, randomized and
open-label AVOCADO (Aspirin Vs/Or Clopidogrel in
Aspirin-resistant Diabetics inflammation Outcomes)
study. The AVOCADO study enrolled 304 consecutive pa-
tients aged between 30 and 80 years, presenting to the
outpatient clinic of the Central Teaching Hospital of the
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August 2010, with DM2 diagnosed at least 6 months prior
to their presentation, who had been taking enteric
coated ASA tablets at a dose of 75 mg per day for at least
3 months for primary or secondary cardiovascular preven-
tion. Exclusion criteria included: diet-controlled DM2,
treatment with antiplatelet drugs other than ASA, treat-
ment with anticoagulants, chronic treatment with non-
steroidal anti-inflammatory drugs (NSAID) or self-
reported use of NSAIDs within the last 10 days, coexisting
contraindications to ASA treatment, ASA intolerance,
platelet count below 100,000/mm3 or above 450,000/mm3,
hemoglobin concentration below 8 g/dL, a history of
bleeding diathesis or other coagulation disorders, malig-
nant disease (current or therapy within the past 5 years),
connective tissue disease, end-stage renal disease requiring
dialysis, acute coronary syndrome, coronary angioplasty
or coronary artery bypass grafting in the last 12 months
prior to enrollment into the study, active and clinically
overt inflammation, exacerbation of chronic heart failure,
acute complications of diabetes and other acute medical
conditions requiring unplanned hospitalization in the last
8 weeks prior to the study, and surgical procedures in
the previous 8 weeks. A more detailed characteristic of
the AVOCADO study population has been published
previously [30-32].
The study was conducted in accordance with the
current version of the Declaration of Helsinki. The local
ethics committee of the Medical University of Warsaw
approved both the AVOCADO study protocol and the
informed consent form. A written informed consent was
obtained from all patients.
For the current analysis, only DM2 patients treated
with oral antidiabetic drugs were selected from the
AVOCADO study (patients treated with insulin in
monotherapy or in combination were excluded).Data collection and laboratory tests
Demographic information, medical history, medications,
and lifestyle habits were obtained from all patients
through a personal interview and a review of medical
charts. A thorough physical examination with anthro-
pometric measurements was also conducted.
Venous blood samples were collected in the morning
(between 8 a.m. and 9 a.m.) following an overnight fast,
2-3 hours after the last ASA dose (one day before testing
all patients were reminded by a telephone call to take
their daily ASA at least 2 hours before the appointment).
Regular laboratory testing was performed at the laboratory
of the Central Teaching Hospital, Medical University of
Warsaw using standard techniques and included fasting
glycemia, glycated hemoglobin (HbA1c), lipid profile, high-
sensitivity C-reactive protein (hsCRP), serum creatinine,urea and uric acid concentrations, complete blood cell and
platelet counts, and coagulation tests.
Serum (for TXB2, insulin, C-peptide and adipokines
concentrations measurements) and citrated plasma (for
von Willebrand factor activity measurement) had been
obtained from venous blood by centrifugation at 1000 g
for 15 min at 4°C, and aliquots had been stored at -80°C
until patients' enrollment was completed - afterwards the
samples were defrosted and appropriate measurements
were performed. Concentrations of functional epitope of
von Willebrand factor were measured in citrate plasma
samples using von Willebrand Factor Activity Kit®, accor-
ding to the manufacturer’s instructions (American Diag-
nostica Inc., USA). Von Willebrand factor activity was
expressed as percentage (100% corresponds to 1 IU/mL).
Measurement of serum thromboxane B2
Whole blood for TXB2 was allowed to clot at 37°C for
1 hour, after which the serum was separated by centrifu-
gation and stored at -80°C, as described above. Serum
TXB2 was measured with an enzyme immunoassay kit
(Thromboxane B2 EIA Kit®), according to the manufac-
turer’s instructions (Cayman Chemicals, USA). Samples
with results outside the standard curve were re-assayed
with appropriate dilutions. Given the unequivocal data in
the literature, we have decided not to adopt any thresh-
old for serum TXB2 concentration that would define
HAPR [33-35]. Instead, we regarded serum TXB2 con-
centration as a continous variable, dividing patients into
groups consistent with serum TXB2 concentration quar-
tiles. Thus, we compared patients with serum TXB2 con-
centrations in increasing quartiles. In order to determine
the risk factors for HAPR, we analyzed which variables
were predictive of serum TXB2 concentration above the
upper (third) quartile. Additionally, we analyzed which
variables were predictive of serum TXB2 concentration
above the median (second quartile).
Assessment of metabolic control of diabetes
Glycemic and lipid treatment targets were defined in
accordance with the American Diabetes Association
guidelines as achieving HbA1c below 7%, LDL concen-
tration below 100 mg/dL in patients without overt
coronary artery disease and below 70 mg/dL in patients
with coronary artery disease, HDL concentration above
50 mg/dL in women and above 40 mg/dL in men, and
triglyceride concentration below 150 mg/dL [36].
Assessment of insulin resistance
Insulin and C-peptide serum concentrations were
measured using Elecsys Insulin Assay® and Elecsys
C-Peptide Assay®, respectively, according to the manufac-
turer’s instructions (Roche Diagnostics, Germany) with
electrochemiluminescence, on Elecsys 2010 analyzer
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stasis Model Assessment-Insulin Resistance (HOMA-IR)
index was then calculated based on the following formula:
insulin concentration × fasting glycemia × 0.0555/22.5,
with insulin concentration expressed in μIU/mL and
fasting glycemia expressed in mg/dL.
Assessment of adipose tissue metabolic activity
High-molecular weight (HMW) adiponectin, leptin and
resistin concentrations were measured in serum using
Human High Molecular Weight Adiponectin ELISA®
(Millipore Corporation, USA), Human Leptin Quantikine
ELISA Kit® (R&D Systems Inc., USA) and Human Resistin
Quantikine ELISA Kit® (R&D Systems Inc., USA),
respectively.
Assessment of compliance to ASA therapy
Compliance to ASA therapy was determined based upon
patients' statements and serum TXB2 concentration
measurement. Based on the literature, optimal compli-
ance to ASA therapy was confirmed by serum TXB2
concentrations below 7200 pg/mL [9]. Only patients
with optimal compliance were included in the final
analysis.
Statistical analysis
Statistical analysis was performed using SAS® software,
version 9.2. Normal distribution of variables was
assessed using the Shapiro-Wilk test and histograms.
When normally distributed, quantitative variables are
presented as a mean value ± standard deviation (SD),
when non-normally distributed - as a median and inter-
quartile range (IQR). Qualitative variables are presented
as absolute and relative frequencies. Statistical signifi-
cance of trends across increasing quartiles of serum
TXB2 concentration was assessed: for quantitative vari-
ables with Jonckheere-Terpstra test, for qualitative vari-
ables - with Cochran-Armitage test for trend. Univariate
and multivariate logistic regression analyses were
performed to determine the predictive factors of serum
TXB2 concentration above the upper quartile and of
serum TXB2 concentration above the median. In a
multivariate logistic regression model all factors which
were found to be significant in univariate analyses were




Out of 304 patients enrolled in the AVOCADO study,
complete clinical data and blood samples were available
from 295 patients, including 195 patients treated only
with oral antidiabetic agents. Additionally, 9 patients
were excluded from the study based on suspected ASAnon-compliance (serum TXB2 concentration >7200 pg/mL),
resulting in a total of 186 patients included in the
final analysis.
Study group characteristics
Mean age of the study population was 67.7 (±8.7) years.
Women constituted 50.5% of the study group. Median
serum TXB2 concentration was 149.1 pg/mL (minimum:
2.7 pg/mL, maximum: 5812.3 pg/mL). Figure 1 repre-
sents the distribution of serum TXB2 concentration in
the study group. Clinical and laboratory characteristics
of the study group in relation to quartiles of serum
TXB2 concentration are shown in Tables 1 and 2. Patient
recruitment began in January 2008, which explains why
only two-thirds of the patients received metformin (ac-
cording to the guidelines valid at the time, metformin
had not yet been recommended for the majority of
patients with DM2). There were significant trends in the
use of metformin and sulfonylurea derivatives associated
with serum TXB2 concentrations: the frequency of
metformin treatment increased and that of sulfonylurea
derivatives decreased with increasing quartiles of serum
TXB2 (Table 1). As the direction of this relationship
seemed surprising, given the potential antiplatelet
properties of metformin, we compared patients receiving
and not receiving metformin, and those receiving and
not receiving sulfonylurea derivatives (Table 3) [37]. In
comparison to patients not receiving metformin, patients
treated with metformin were on average 4 years younger
and had a significantly higher BMI (contrary trends were
observed for therapy with sulfonylurea derivatives),
which could explain the observed relationship of
diabetes treatment with increasing quartiles of serum
TXB2, given a negative association of serum TXB2 level
with age and its positive association with BMI. There-
fore, in order to avoid a methodological bias in deter-
mining the risk factors for HAPR, we have decided not
to include diabetes treatment in the logistic regression
analysis.
Predictors of serum TXB2 concentration above the upper
quartile
In univariate analyses, the only predictive factors for
serum TXB2 level above the upper (third) quartile were
younger age (odds ratio, OR [per 5 years] 0.762, 95%
confidence interval, CI 0.622-0.932, p = 0.008) and
higher BMI (OR [per 5 kg/m2] 1.615, 95% CI 1.106-
2.360, p = 0.013) - both proved to be independent risk
factors in multivariate analysis (Table 4).
Predictors of serum TXB2 concentration above the
median
In univariate analyses, predictive factors for serum TXB2
level above the median (second quartile) were: younger
Figure 1 Distribution of serum thromboxane B2 concentration in
the study group. TXB2 - thromboxane B2. The box plot represents the
median, the interquartile range, and the minimum and maximum
value.
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0.001), higher BMI (OR [per 5 kg/m2] 1.706, 95% CI
1.205-2.416, p = 0.003), lower HMW adiponectin
concentration (OR [per 1 μg/mL] 0.777, 95% CI 0.665-
0.907, p = 0.001), and triglyceride concentration above
150 mg/dL (OR 2.880, 95% CI 1.491-5.562, p = 0.002).
In multivariate analysis only younger age and lower
HMW adiponectin concentration (with borderlinesignificance) were risk factors for serum TXB2 above the
median (Table 5).
Discussion
In the studied group of DM2 patients, age proved to be
the most important predictive factor of laboratory re-
sponse to ASA therapy. Some published data suggest an
association between HAPR and older age, which could
be explained by an increasing number of comorbidities
and other coexisting conditions, including risk factors
for HAPR [38]. However, our analysis revealed younger
age as an independent predictor for HAPR. Similar
results have been previously reported by Maree et al.
[34]. In a group of 131 stable cardiovascular patients
taking 75 mg of enteric-coated ASA daily, HAPR,
defined as serum TXB2 concentrations above 2200 pg/mL,
was found in 44% of patients. In a multivariate analysis,
younger age and higher body weight were the only predic-
tive factors of HAPR. In all cases of HAPR in vitro incuba-
tion of participants’ blood samples with ASA solution
resulted in a complete inhibition of platelet aggregation,
which implied a pharmacokinetic mechanism of HAPR
(i.e. related to diminished bioavailability of ASA) [34].
Lower bioavailability of ASA in younger patients may be
attributable to a higher activity of plasma, hepatic and in-
testinal esterases, which hydrolyze ASA to salicylic acid -
a product deprived of permanent antiplatelet activity.
Review of published literature confirms that plasma ester-
ase activity, including aspirin esterase, decreases in older
people burdened with additional risk factors, especially a
coexisting inflammatory state [39-41]. Furthermore, com-
pared with healthy volunteers, higher aspirin esterase ac-
tivity has been reported in DM2 patients, leading to faster
ASA hydrolysis and HAPR [42]. These data suggest that
the inverse relationship between serum TXB2 concentra-
tion and age observed in our study could arise from age-
related differences in ASA bioavailability in DM2 patients.
It can be hypothesized that in younger DM2 patients a
total daily dose of ASA higher than 75 mg may be
required to exhibit full antiplatelet effect. Low doses of
ASA are a known risk factor for HAPR and increasing
ASA doses have been reported to overcome HAPR
[6,19,25].
The etiology of HAPR in younger DM2 patients might
involve the above described pharmacokinetic mechanism,
as well as pharmacodynamic abnormalities. A higher rate
of platelet turn-over resulting in a faster recovery of COX-
1 activity after ASA administration has been proposed as
a potential pharmacodynamic mechanism of HAPR in
DM2 after several studies demonstrated increased platelet
aggregation at the end of the 24-hour dosing interval,
compared to platelet aggregation measured early after
ASA ingestion [43-45]. In 100 DM2 patients receiving
enteric-coated ASA 100 mg once daily, serum TXB2
Table 1 Clinical characteristics of the study group in relation to platelet reactivity, expressed as quartiles of serum
thromboxane B2 concentration
Clinical parameters TXB2 TXB2 TXB2 TXB2 p
<50 pg/mL [50-150 pg/mL) [150-450 pg/mL) ≥450 pg/mL
n = 45 n = 49 n = 47 n = 45
Age [years] 69.2 (±8.8) 70.0 (±7.4) 66.7 (±8.7) 64.7 (±9.3) 0.0062
Female gender [n (%)] 27 (60.0%) 24 (49.0%) 20 (42.6%) 23 (51.1%) 0.32
Duration of diabetes [years] 5 (2-10) 6 (3-10) 6 (3-11) 5 (2-7) 0.36
Anthropometric parameters
BMI [kg/m2] 29.1 (±4.3) 29.4 (±4.4) 31.2 (±5.4) 31.8 (±5.3) 0.005
SBP [mmHg] 142.6 (±19.4) 141.3 (±18.8) 135.3 (±16.7) 141.9 (±19.3) 0.64
DBP [mmHg] 79.3 (±9.5) 80.9 (±12.1) 79.8 (±10.7) 81.0 (±13.4) 0.56
Diabetes treatment [n (%)]
Metformin 29 (64.4%) 24 (49.0%) 35 (74.5%) 36 (80.0%) 0.0188
Sulfonylurea derivatives 30 (66.7%) 40 (81.6%) 35 (74.5%) 22 (48.9%) 0.0485
Sulfonylurea derivatives and metformin 15 (33.3%) 18 (36.7%) 25 (53.2%) 14 (31.1%) 0.74
Acarbose 2 (4.4%) 5 (10.2%) 7 (14.9%) 5 (11.1%) 0.22
DPP-4 inhibitors, TZD and glinides 0 0 0 0 -
Coexisting conditions [n (%)]
Hypertension 42 (93.3%) 45 (91.8%) 41 (87.2%) 42 (93.3%) 0.80
Dyslipidaemia 37 (82.2%) 45 (91.8%) 40 (85.1%) 35 (77.8%) 0.39
CAD 19 (42.2%) 31 (63.3%) 22 (46.8%) 26 (57.8%) 0.39
Previous MI 9 (20.0%) 16 (32.7%) 14 (29.8%) 10 (22.2%) 0.91
Chronic HF 12 (26.7%) 21 (42.9%) 15 (31.9%) 18 (40.0%) 0.38
- NYHA class I 1 (2.2%) 6 (12.3%) 2 (4.3%) 5 (11.1%)
0.23
- NYHA class II 8 (17.8%) 9 (18.4%) 10 (21.3%) 11 (24.4%)
- NYHA class III 3 (6.7%) 6 (12.3%) 3 (6.4%) 2 (4.4%)
- NYHA class IV 0 0 0 0
Previous stroke or TIA 5 (11.1%) 5 (10.2%) 4 (8.5%) 2 (4.4%) 0.24
Current smoking 3 (6.7%) 3 (6.1%) 6 (12.8%) 6 (13.3%) 0.16
Treatment of concomitant diseases [n (%)]
β-blocker 33 (73.3%) 29 (59.2%) 32 (68.1%) 32 (71.1%) 0.96
- carvedilol or nebivolol 4 (8.9%) 6 (12.3%) 4 (8.5%) 1 (2.2%) 0.16
ACE-I or ARB 36 (80.0%) 39 (79.6%) 37 (78.7%) 34 (75.6%) 0.60
Aldosterone antagonist 1 (2.2%) 5 (10.2%) 6 (12.8%) 4 (8.9%) 0.23
Other diuretics 25 (55.6%) 21 (42.9%) 26 (55.3%) 21 (46.7%) 0.97
CCB 18 (40.0%) 11 (22.5%) 18 (38.3%) 23 (51.1%) 0.13
Statin 34 (75.6%) 40 (81.6%) 34 (72.3%) 31 (68.9%) 0.27
Relative frequency, standard deviations and interquartile ranges are presented in parentheses.
TXB2 - thromboxane B2; BMI - body mass index; SBP - systolic blood pressure; DBP - diastolic blood pressure; DPP-4 - dipeptidylpeptidase-4; TZD - thiazolidinediones;
CAD - coronary artery disease; MI - myocardial infarction; HF – heart failure; NYHA - New York Heart Association; TIA - transient ischemic attack;
ACE-I - angiotensin-converting enzyme inhibitor; ARB - angiotensin receptor blocker; CCB - calcium channel blocker. Bold font indicates p-values ≤0.05.
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ASA intake was measured by Rocca et al. [45]. Younger
age, higher BMI and higher mean platelet volume (MPV)
were independent predictors of the most rapid increase in
TXB2 concentration. Positive correlations between TXB2
recovery rate and MPV as well as between TXB2 recoveryrate and the percentage of newly-released, messenger
ribonucleic acid (mRNA)-positive platelets were
observed, which suggests that the recovery of COX-1
activity during the 24-hour dosing interval largely
depends on accelerated platelet turn-over. Most impor-
tantly, in a subgroup of 33 patients with the most rapid
Table 2 Laboratory characteristics of the study group in relation to platelet reactivity, expressed as quartiles of serum
thromboxane B2 concentration
Laboratory parameters TXB2 TXB2 TXB2 TXB2 p
<50 pg/mL [50-150 pg/mL) [150-450 pg/mL) ≥450 pg/mL
n = 45 n = 49 n = 47 n = 45
Insulin resistance parameters and adipokines
HOMA-IR 3.23 (2.29-4.94) 3.54 (2.42-6.07) 4.48 (2.62-7.29) 4.25 (3.16-8.12) 0.019
Insulin [μIU/mL] 11.22 (7.66-15.50) 11.54 (8.88-20.17) 14.24 (9.30-21.00) 15.44 (10.01-21.09) 0.076
C-peptide [ng/mL] 3.756 (2.964-4.680) 3.852 (3.096-5.556) 3.948 (3.360-5.316) 4.260 (3.552-4.908) 0.095
HMW adiponectin [μg/mL] 3.86 (2.28-5.20) 3.15 (2.20-5.54) 2.31 (1.55-3.24) 2.41 (1.65-3.40) 0.002
Leptin [ng/mL] 14.52 (9.40-22.16) 18.40 (9.02-26.09) 15.54 (9.68-33.02) 19.21 (8.24-37.10) 0.36
Resistin [ng/mL] 6.85 (5.21-9.73) 7.50 (5.91-8.60) 6.55 (5.58-7.97) 6.66 (4.91-8.69) 0.41
Glycemic control parameters
HbA1c [%] 6.2 (6.1-6.6) 6.5 (6.0-7.1) 6.5 (5.9-7.2) 6.6 (6.3-7.6) 0.018
HbA1c target achieved 38 (84.4%) 33 (67.4%) 32 (68.1%) 29 (64.4%) 0.051
Fasting glycemia [mg/dL] 116 (102-130) 120 (107-136) 120 (104-147) 126 (108-155) 0.041
Lipid control parameters
TC [mg/dL] 159.3 (±46.8) 165.3 (±36.6) 178.1 (±34.0) 164.7 (±34.0) 0.12
LDL cholesterol [mg/dL] 83.3 (±28.4) 87.5 (±31.3) 96.4 (±30.9) 88.9 (±29.4) 0.23
LDL cholesterol target achieved 22 (48.9%) 22 (44.9%) 16 (34.0%) 22 (48.9%) 0.73
HDL cholesterol [mg/dL] 47.8 (±10.1) 51.7 (±17.8) 49.4 (±12.5) 46.4 (±11.2) 0.58
HDL cholesterol target achieved 25 (55.6%) 22 (44.9%) 18 (38.3%) 22 (48.9%) 0.42
TG [mg/dL] 122.0 (±46.0) 125.6 (±59.5) 158.0 (±77.7) 153.2 (±71.5) 0.010
TG target achieved 35 (77.8%) 38 (77.6%) 27 (57.5%) 27 (60.0%) 0.016
Other laboratory parameters
PLT [103/μL] 214.5 (±64.7) 229.5 (±59.0) 241.4 (±67.1) 224.8 (±44.8) 0.30
MPV [fL] 10.0 (±1.3) 9.9 (±1.2) 9.5 (±1.1) 10.0 (±1.2) 0.65
WBC [103/μL] 6.46 (±1.31) 6.75 (±1.83) 7.26 (±1.53) 6.83 (±1.95) 0.24
RBC [106/μL] 4.73 (±0.43) 4.58 (±0.54) 4.67 (±0.46) 4.66 (±0.40) 0.83
Hemoglobin [g/dL] 14.0 (±1.2) 13.8 (±1.3) 14.1 (±1.2) 14.0 (±1.2) 0.77
Hematocrit [%] 42.2 (±3.5) 41.2 (±3.8) 42.2 (±3.5) 41.6 (±3.3) 0.99
Fibrinogen [mg/dL] 417.2 (±101.3) 443.8 (±106.7) 440.8 (±126.2) 408.3 (±95.5) 0.59
vWF activity (%) 138.3 (96.8-157.9) 141.0 (112.7-185.1) 134.3 (102.3-199.1) 111.8 (89.6-165.1) 0.49
APTT [s] 29.3 (±3.7) 29.2 (±3.2) 28.9 (±4.7) 29.2 (±4.0) 0.82
INR 0.97 (0.93-1.03) 0.96 (0.91-1.00) 0.95 (0.92-0.98) 0.98 (0.92-1.02) 0.79
hsCRP [mg/dL] 1.6 (1.1-3.3) 2.9 (1.5-4.9) 3.2 (2.2-5.7) 2.7 (1.4-4.4) 0.023
eGFR [mL/min/1,73m2] 74.3 (62.1-90.3) 68.4 (59.3-87.7) 78.1 (67.0-93.2) 77.1 (63.7-91.2) 0.24
Urea [mg/dL] 41.0 (±11.2) 43.3 (±12.7) 37.6 (±11.4) 39.0 (±10.0) 0.092
UA [mg/dL] 5.9 (±1.4) 5.6 (±1.6) 5.6 (±1.4) 5.8 (±1.4) 0.91
Relative frequency, standard deviations and interquartile ranges (IQR) are presented in parentheses.
TXB2 - thromboxane B2; HOMA-IR - Homeostasis Model Assessment-Insulin Resistance; HMW - high-molecular weight; HbA1c - glycated hemoglobin; TG - triglycerides;
HDL - high-density lipoprotein; TC - total cholesterol; LDL - low-density lipoprotein; PLT - platelet count; MPV - mean platelet volume; WBC - white blood cell count;
RBC - red blood cell count; vWF - von Willebrand factor; APTT - activated partial thromboplastin time; INR - international normalized ratio;
hsCRP - high-sensitivity C-reactive protein; eGFR - estimated glomerular filtration rate; UA - uric acid. Bold font indicates p-values ≤0.05.
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men to 100 mg b.i.d. resulted in a persistent inhibition
of COX-1 activity, while changing to 200 mg o.d.
displayed an intermediate pattern of TXB2 recovery[45]. Several other platelet function studies conducted
in DM2 patients, confirmed the beneficial effect of a
twice-daily ASA regimen compared to an equivalent
ASA dose given once daily [46-49].
Table 3 Comparison of patients receiving and not




Age [years] 66.2 (±8.4) 70.6 (±8.8) 0.001
BMI [kg/m2] 31.0 (±4.9) 29.1 (±4.9) 0.014
Sulfonylurea derivatives treatment p
Yes No
Age [years] 68.4 ± 9.0 66.1 ± 8.0 0.093
BMI [kg/m2] 29.8 ± 5.0 31.6 ± 4.7 0.025
BMI - body mass index. Bold font indicates p-values ≤0.05.
Table 5 A predictive model of serum thromboxane B2
concentration above the median
Variables OR 95% CI p
Age 0.825 0.686-0.993 0.042
[5 years]
BMI 1.376 0.978-1.936 0.067
[5 kg/m2]
HMW adiponectin 0.857 0.734-1.000 0.050
[1 μg/mL]
TG ≥ 150 mg/dL 1.651 0.829-3.287 0.154
OR - odds ratio; CI - confidence interval; BMI - body mass index; HMW -
high-molecular weight; TG - triglycerides. Bold font indicates p-values ≤0.05.
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a twice-daily ASA regimen may be favorable compared
to merely increasing ASA given as a single daily dose.
This approach might be of value especially in younger
DM2 patients, as it would counteract both the pharma-
cokinetic (esterase-activity-dependent) and the pharma-
codynamic (related to the increased platelet turn-over)
mechanism of HAPR. However, no threshold allowing
identification of such "younger" patients can be war-
ranted based on the results of our study, as the observed
difference in age between the patients with TXB2 con-
centrations above the upper quartile and the patients
with TXB2 concentrations below the lower quartile was
only 4.5 years. Therefore, clinical significance of this
finding should be verified by further studies.
The second independent predictor of serum TXB2
concentration above the upper quartile in the studied
population was a higher BMI. In a univariate analysis,
higher BMI was also significantly predictive of serum
TXB2 concentration above the median, however, this
effect was attenuated in a multivariate analysis. Indices
of obesity, including higher BMI and body weight, as
well as markers of visceral obesity, such as waist circum-
ference and waist-hip ratio (WHR) have been previously
described as risk factors for HAPR [6,21,26,27,34,38].
Platelet hyperaggregability in obese patients may result
from enhanced lipid peroxidation due to increased
generation of intraplatelet reactive oxygen species and
low-grade inflammation, which may be related to co-
existing metabolic (e.g. lipid) abnormalities [50-53]. FattyTable 4 A predictive model of serum thromboxane B2
concentration above the upper quartile
Variables OR 95% CI p
Age 0.785 0.637-0.967 0.023
[5 years]
BMI 1.495 1.021-2.190 0.039
[5 kg/m2]
OR - odds ratio; CI - confidence interval; BMI - body mass index. Bold font
indicates p-values ≤0.05.acid peroxidation may, in turn, induce changes in the
physicochemical properties of platelet plasma membrane
and formation of products which activate platelets by
binding to their surface receptors, thus, triggering HAPR
in a pharmacodynamic manner [25]. Nevertheless, the
observed association between BMI and HAPR in our
study, might have also resulted from reduced bioavail-
ability of an enteric-coated ASA preparation, represen-
ting a pharmacokinetic mechanism of HAPR. Recently,
in a group of 400 healthy volunteers, Grosser et al. [54]
have assessed platelet aggregation and serum TXB2 con-
centration after ingestion of a single oral dose of enteric-
coated versus immediate-release ASA. Ingestion of an
immediate-release preparation led to a substantial inhi-
bition of platelet aggregation and TXB2 generation in all
of the patients, while a single dose of enteric-coated
preparation was associated with high rates of HAPR -
higher if assessed 4 hours after ASA intake compared to
the measurement performed 8 hours after ASA inges-
tion. Ex vivo addition of ASA to blood samples of non-
responders resulted in amelioration of HAPR, suggesting
that in those patients HAPR was related to reduced and
delayed absorption of enteric-coated ASA tablets [54]. In
our study, we used enteric-coated ASA preparations and
collected blood samples relatively early (i.e. 2-3 hours)
after ASA ingestion. The extent to which this approach
might have influenced the results of our analysis remains
uncertain, since in the study by Grosser et al. [54], pro-
longation of enteric-coated ASA treatment to one week
led to overcoming of HAPR in all but one of the 27
patients who were unresponsive to a single dose of the
enteric-coated preparation. Still, other studies have dem-
onstrated that compared to immediate-release prepara-
tions, enteric-coated ASA tablets are less effective at
inhibiting TXB2 generation, even if taken chronically
[55,56]. Interestingly, in these studies, higher body
weight was found to be predictive of HAPR - analo-
gously as in the above cited study by Maree et al.
[34,55,56]. It has been hypothesized that due to reduced
bioavailability, low doses of enteric-coated ASA may be
Kaplon-Cieslicka et al. Cardiovascular Diabetology 2014, 13:112 Page 9 of 12
http://www.cardiab.com/content/13/1/112insufficient in heavier patients with a larger volume of
distribution [34]. Thus, a conversion from 75 mg daily
of enteric-coated ASA to 75 mg daily of immediate-
release ASA has been suggested by Peace et al. [56] for
patients over 90 kg, with a further dose increase to 150
mg daily in patients over 120 kg.
Despite significant differences in HOMA-IR across in-
creasing quartiles of serum TXB2 concentration, logistic
regression analysis did not reveal HOMA-IR as a pre-
dictive factor of HAPR in the studied population. This
might suggest that the observed relationship of higher
TXB2 levels with lower HMW adiponectin concentra-
tions is not associated with its insulin-sensitizing proper-
ties. Moreover, HMW adiponectin remained borderline
significant even after correction for BMI. No association
of serum TXB2 concentration with neither leptin nor
resistin levels would also imply that the relationship of
low HMW adiponectin concentrations with increased
platelet reactivity is independent from its insulin-
sensitizing course of action.
To our knowledge, this is the first study to demonstrate
the association of lower HMW adiponectin concentration
with higher serum TXB2 level in aspirin-treated patients.
Under physiological conditions, adiponectin is the hormone
most abundantly secreted from adipocytes, with serum
concentrations ranging between 3 and 30 μg/mL in healthy
individuals [57]. In the blood, it circulates as three different
oligomeric complexes, including low-molecular weight
(a trimer), medium-molecular weight (a hexamer) and
HMW adiponectin - the latter is considered the most bio-
logically active form and constitutes approximately half of
adiponectin's plasma amount [57]. In contrast to leptin and
resistin, adiponectin levels have been shown to correlate in-
versely with BMI, the amount of visceral adipose tissue and
insulin resistance [58-60]. Low adiponectin concentration is
an independent predictive factor of the future development
of DM2 [61]. Hypoadiponectinemia has been also associ-
ated with an increased risk of metabolic syndrome, hyper-
lipidemia, nonalcoholic steatohepatitis and polycystic ovary
syndrome, as well as hypertension, coronary artery disease
and acute coronary syndrome [59,60]. Adiponectin acts via
two distinct types of receptors, identified in skeletal muscles
(type 1 receptor) and liver (type 2 receptor), as well as on
the surface of pancreatic β-cells, endothelial cells, smooth
muscle cells, cardiomyocytes, monocytes, macrophages and
platelets. It improves insulin sensitivity by increasing fatty
acid β-oxidation and glucose utilization, as well as decreas-
ing lipogenesis and gluconeogenesis in the liver. Unlike
leptin and resistin, adiponectin has also been shown to
exert anti-inflammatory and antiatherogenic effects. Its
protective influence on the endothelium results largely
from the enhancement of NO generation and attenuation
of oxidative stress [57,59,60]. Recently, Okada-Iwabu et al.
[62] have discovered an orally active, synthetic adiponectinreceptor agonist (AdipoRon), which was found to
ameliorate insulin resistance, glucose intolerance and
diabetes in experimental rodent models, offering a new
promising therapeutic approach to DM2 prevention
and treatment.
Although antiplatelet properties of adiponectin have
been already described before, the existing evidence stems
mostly from in vitro studies and the exact mechanism of
action remains unknown. Data from the literature imply a
possibility of both, a direct and an indirect effect of adipo-
nectin on platelet function. It has been demonstrated that
human and animal platelets contain mRNA for adiponec-
tin receptors and that in healthy volunteers, as well as in
patients with the metabolic syndrome, platelets express
both types of adiponectin receptors on their surface
[63,64]. In comparison to wild-type mice, adiponectin
knockout mice showed enhanced platelet aggregation in-
duced by adenosine diphosphate (ADP) and collagen, and
accelerated thrombus formation on carotid arterial injury
[63]. In vitro incubation of platelets with adiponectin de-
creased spontaneous, epinephrine- and ADP-induced
platelet aggregation in several, although not in all studies
[64-66]. Furthermore, adiponectin could influence platelet
reactivity also in an indirect manner, by counteracting the
deleterious effects of perioxide generation and by increas-
ing the activity of the endothelial NO synthase (eNOS),
NO generation, endothelial COX-2 expression and prosta-
cyclin production [67-69]. Considerably less evidence is
available from the clinical studies. In a group of 30 healthy
volunteers and 30 patients with the metabolic syndrome,
adiponectin concentration correlated negatively with
plasma soluble P-selectin and soluble CD40 ligand
(CD40L) levels, as well as with epinephrine- and ADP-
induced platelet aggregation [64]. In 277 patients with
DM2 low concentration of adiponectin was an independent
predictive factor for the formation of leukocyte-platelet
aggregates [70]. So far, only one study has investigated the
relationship between adiponectin level and laboratory
response to ASA. Following the incubation of blood
samples with ASA solution, Takahashi et al. assessed
platelet reactivity with Platelet Function Analyzer-100®
(PFA-100®) in 168 men without known cardiovascular
disease [5]. Poor responsiveness to ASA was defined as
collagen-epinephrine closure time (CEPI-CT) below
250 seconds. The subgroup of 40 poor responders was
characterized by a higher prevalence of diabetes and,
surprisingly, by a higher adiponectin concentration
(8.8 ± 4.1 μg/mL versus 7.3 ± 2.9 μg/mL, p = 0.010).
These results, however, were not verified with a multi-
variate analysis [5].
In the present study, we observed associations of
serum TXB2 concentration with fasting glycemia, HbA1c
proportion and triglyceride concentration. Nevertheless,
the results of logistic regression analysis did not support
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ment targets [i.e. HbA1c below 7% and triglyceride level
below 150 mg/dL] and serum TXB2 levels. There was no
association of serum TXB2 concentration with total,
LDL or HDL cholesterol. This is not in concordance
with the data from the previous studies, which have re-
ported a significant relationship between HAPR and the
indices of metabolic control of diabetes [6,7,18-22,24].
However, a more thorough analysis of the available lit-
erature reveals that studies which showed such relation-
ship mostly included patients with poor or suboptimal
diabetes control and, in some cases, patients with dia-
betes and healthy controls. Such characteristics of a
studied population would result in a broader spectrum
of values of the analyzed parameters, which could faci-
litate a demonstration of significance between the
observed differences. Furthermore, the higher glucose,
triglyceride and cholesterol concentrations, the higher
the probability of development of platelet function dis-
orders severe enough to be reflected by laboratory tests.
On the other hand, patients included in our analysis
comprised a more homogeneous group and were charac-
terized by a relatively good metabolic control, with
median HbA1c of 6.5% [in comparison to 7.3% in a study
by Cohen et al., and 9.4% in a study by Watala et al.],
mean total cholesterol of 166.9 mg/dL (in comparison to
207 mg/dL in a study by Watala et al.), mean LDL chol-
esterol of 89.1 mg/dL (in comparison to 135.4 mg/dL in
a study by Hovens et al.), mean HDL cholesterol of 48.9
mg/dL (in comparison to 43 mg/dL in a study by Watala
et al.), and mean triglyceride concentration of 139.6 mg/
dL (in comparison to 159.4 mg/dL in a study by Hovens
et al.) [18,20,21]. These differences may at least partly
account for the lack of relationship between platelet
reactivity and metabolic control in our study. Another
explanation for the lack of significant association be-
tween serum TXB2 concentration and glycemic control
may derive from the findings of Russo et al., who proved
that incubation of platelets with hyperosmolar glucose
solutions prevented ASA-induced activation of the NO -
cGMP - cGMP-dependent protein kinase pathway and,
consequently, reduced the ability of ASA to inhibit
platelet responses to agonists but did not modify ASA-
dependent inhibition of TXB2 synthesis [17].
Limitations of the study
In our study, we evaluated on-aspirin platelet reactivity by
measuring serum TXB2 concentration. We did not use
light transmission aggregometry (LTA), which is tradition-
ally considered “the gold standard” for platelet function
assessment. However, as mentioned above, measurement
of serum TXB2 level is one of the methods recommended
by the Working Group on Antiplatelet Drugs Resistance
[10]. Moreover, LTA has some important limitations, suchas lack of standardization, relatively little reproducibility
of results, little correlation with other methods of platelet
function assessment and the use of platelet-rich plasma
which poorly reflects the in vivo conditions of platelet ac-
tivation. Most importantly, measurement of concentration
of serum TXB2 (a metabolite of TXA2 which is the direct
product of COX-1) is the most specific method for the
assessment of laboratory response to ASA therapy.
Given the fact that in DM2 patients treated with a
single daily dose of ASA, accelerated COX-1 activity re-
covery has been previously reported (as discussed above),
we might have obtained a wider spectrum of serum
TXB2 concentrations if we had collected blood samples
24 hours instead of 2-3 hours after ASA ingestion. This
might have increased the statistical power of our analysis.
Characteristics of the study group did not include some
potentially relevant clinical data, such as prevalence of
microvascular complications (retinopathy, microalbumi-
nuria), some macrovascular complications (peripheral
artery disease, asymptomatic carotid stenosis) and neuro-
pathic or mixed diabetes complications, i.e. diabetic foot
syndrome - we did not have these data in the AVOCADO
study. Also, data on the use of proton-pump inhibitors
were not available.
Another limitation of this study is a relatively small
number of patients.
Conclusions
In the studied group of DM2 patients, the most impor-
tant independent predictor of HAPR was younger age.
Younger patients with DM2 may therefore require total
daily ASA doses higher than 75 mg, preferably as a
twice-daily regimen, to achieve full therapeutic effect.
Higher BMI and lower HMW adiponectin concentration
were also associated with less potent ASA effect. This is
the first study to demonstrate an association of lower
adiponectin concentration with higher serum TXB2 level
in patients treated with ASA.
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